|
|
||||
|
SU11248: Genesis of a New Cancer Drug
The development of a promising RTK inhibitor
Email: Joseph Schlessinger - joseph.schlessinger@yale.edu The Scientist 2005, 19(7):17
|
||||
|
|
||||
|
Every drug has a story behind it. Here, I condense 25 years of hard work by hundreds of people by focusing on key events and characters that shaped the discovery of SU11248, a new cancer drug. Cancers remain an immense problem, but this story has an affirmative message: Investment in basic research, the mining of that research for promising leads, and the relentless, dedicated development of these leads can yield new therapies.
|
|
|||||||||
|
|||||||||
|